Home arrow Cancer of Penis arrow What is Kidney Cancer? Friday, 21 November 2008



 
Slick RSS
MedicineNet Cancer General
MedicineNet Cancer General
MedicineNet Logo
MedicineNet Depression General
MedicineNet Depression General
MedicineNet Logo
Cancer / Oncology News From Medical News Today
Latest Cancer / Oncology News From Medical News Today.
  • Pediatric Cancer : Alteration Of A Gene Causes Neuroblastoma
    Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma. This discovery may allow the development of new treatments in neuroblastomas.
  • Ortho Biotech Announces NDA Submission For Trabectedin For The Treatment Of Relapsed Ovarian Cancer
    Ortho Biotech Products, L.P. announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States.
  • Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
    ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
  • Bovie Medical Corporation Announces FDA 510(K) Clearance To Market SEER Tissue Resection Device
    Bovie Medical Corporation (the "Company") (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation.
  • GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade™ In Locally Advanced Pancreatic Cancer
    GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade™ (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.